Santarus, Inc. closed out 2004 with a net loss of $82.6 million.
The San Diego company, which makes drugs for gastrointestinal problems, said March 22 that it had revenue of $1.34 million during the year. All revenue was in the fourth quarter.
The company went public in April and spent 2004 building a 280-person sales and marketing organization.
The company trades on the Nasdaq as SNTS. Shares closed March 22 at $5.37.
At year-end the company had $114 million in cash.
Brad Graves
